Lv4
658 积分 2023-01-17 加入
Fremanezumab for the Treatment of Patients With Migraine and Comorbid Major Depressive Disorder
1天前
待确认
World Health Organization Guideline on the Use and Indications of Glucagon-Like Peptide-1 Therapies for the Treatment of Obesity in Adults
6天前
已完结
Obesity and Female Reproductive Health; Is There a Role for Glucagon‐Like Peptide‐1 Receptor Agonists?
21天前
已完结
Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes
21天前
已完结
Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes
22天前
已完结
Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trial
22天前
已完结
The benefits of GLP-1 drugs beyond obesity
22天前
已完结
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
29天前
已完结
GLP-1-based therapies for diabetes, obesity and beyond
1个月前
已完结
Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
皖公网安备34019202002308
